Download PDF
Drug Res (Stuttg)
DOI: 10.1055/a-2724-6878
Original Article

Evaluation of the Migrastatic Properties of Selective MMP-2 Inhibitors in Colorectal Cancer: An In Ovo Approach

Authors

  • Nikunj Parekh

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

  • Mansi Patel

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

  • Praysha Patel

    2   University of Windsor, Windsor, Canada (Ringgold ID: RIN8637)

  • Disha Patel

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

  • Kirtan Patel

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

  • Krishna Thakkar

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

  • Aarti Parmar

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

  • Umang Shah

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

  • Sahil Panjvani

    3   Department of Histopathology, Vadodara Clinical Laboratory, Vadodara, India

  • Samir Patel

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

  • Alkeshkumar Kiritbhai Patel

    1   Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, India (Ringgold ID: RIN130172)

Funding received from CHARUSAT SEED RESEARCH GRANT (RP4/21).
Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Colorectal cancer accounts for about 10% of all cancer diagnoses and is the second leading cause of cancer-related death. Until the cancer has progressed to an advanced stage, colorectal cancer typically shows no symptoms. The medications currently utilized to treat colorectal cancer have serious drawbacks. The aim of the study was to evaluate the ability of newly developed synthetic matrix metalloprotease-2 inhibitors to prevent metastases. This study used computational models to evaluate pharmacokinetic characteristics and ligand-binding affinities for preliminary screening. Later, we used the human colorectal cancer cell line SW620 in an in ovo approach to assess its anti-migratory properties. The chorioallantoic membrane was used to transplant tumor cells. In order to assess migrastatic activity in a preclinical model using an in ovo technique, we measured changes in the chick embryo's total body weight, colon length and body weight, complete blood count and histopathology of the colon, liver and stomach. In addition, the histology of the stomach, liver, colon, and chorioallantoic membrane was taken into account while assessing the activity. We discovered that compound N5 ({4-[(3′-amino[1,1′-biphenyl]-4-carbonyl) amino] phenyl~acetic acid) had the best migrastatic action by blocking matrix metalloprotease-2. The new compound showed potential as a matrix metalloprotease-2 inhibitor compared to doxycycline. A more robust platform was needed for further investigation and progress of novel compound towards clinical setting.

Keywords

Colorectal cancer - metastasis - matrix metalloprotease - chicken egg

Supplementary Material



Publication History

Received: 23 July 2025

Accepted after revision: 06 October 2025

Article published online:
28 November 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany